AI
CERE

Atom Investors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Atom Investors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,835
Closed -$309K – 325
2022
Q1 		$309K Buy
+8,835
New +$258K 0.14% 135

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Atom Investors's CERE Position: Q2 2022 in Review

Atom Investors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2022, closing a stake of 8,835 shares — an estimated $309K sold.

Atom Investors first reported a position in CERE in Q1 2022 and held it in 1 quarter. The position peaked at $309K in Q1 2022. 108 funds tracked by Wall St. Rank hold CERE as of Q2 2022.

  • Atom Investors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Atom Investors sold 8,835 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2022, an estimated $309K.
  • Atom Investors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Atom Investors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $309K in Q1 2022.
  • 108 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2022.

Based on Atom Investors's 13F filing for Q2 2022, filed 15 Aug 2022.